nach oben

International Journal of Hematology

Erschienen in:

01.07.2008 | Letter to the Editor

Relapse of chronic myeloid leukemia-chronic phase 14 years after allogeneic hematopoietic stem cell transplantation

verfasst von: Daigo Akahane, Yoshikazu Ito, Masahiko Sumi, Tetsuzo Tauchi, Yukihiko Kimura, Kazuma Ohyashiki

Erschienen in: International Journal of Hematology | Ausgabe 1/2008

Einloggen, um Zugang zu erhalten

Excerpt

Allogeneic hematopoietic stem cell transplantation (HSCT) used to be a mainstay of treatment strategy for relatively young patients with chronic myeloid leukemia (CML) before the introduction of imatinib mesylate (IM). Relapse after more than 5 years is rare in HSCT-treated CML patients, and only a limited number of CML patients who relapsed after 10 years of HCST have been reported. We report on a CML patient who relapsed with chronic phase disease 14 years after HSCT. The presence of this case suggests the possibility that CML stem cells may remain quiescent for more than 10 years and have the capability of re-growth in post-transplant patients. …

Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood. 1990;75:555–62.PubMed

Socie G, Clift RA, Blaise D, et al. Busulphan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies. Blood. 2001;98:3569–74.CrossRefPubMed

Goldman JM, Rizzo JD, Jabocinski KA, et al. Long term outcome after allogeneic stem cell transplantation for CML [abstract]. Hematol J. 2004;5:98. Abstract no. 266.

Yong ASM, Goldman JM. Case report relapse of chronic myeloid leukaemia 14 years after allogeneic bone marrow transplantation. Bone Marrow Transplant. 1999;23:827–8.CrossRefPubMed

Kearney P, Suter M, Biggs JC. Rapid clonal development in a relapsed CML 11 years post replete allogeneic bone marrow transplantation. Leukemia Res. 2002;26:111–5.CrossRef

Robin M, Guardiola P, Devergie A. A 10-year median follow up study after allogeneic stem cell transplantation for chronic myeloid leukemia in chronic phase from HLA-identical sibling donors. Leukemia. 2005;19:1613–20.CrossRefPubMed

Radich JP, Gooley T, Bryant E, et al. The significance of bcr-abl molecular detection in chronic myeloid leukemia patients “late,” 18 months or more after transplantation. Blood. 2001;98:1701–7.CrossRefPubMed

van Rhee F, Lin F, Cross NCP. Detection of residual leukaemia more than 10 years after allogeneic bone marrow transplantation for chronic myelogenous leukaemia. Bone Marrow Transplant. 1994;14:609–12.PubMed

Goldman JM, Gordon M. Why do chronic myelogenous leukemia stem cells survive allogeneic stem cell transplantation or imatinib: does it really matter? Leuk Lymphoma. 2006;47:1–7.CrossRefPubMed

10.

Jamieson CHM, Ailles LE, Dylla SJ, et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med. 2004;351:657–67.CrossRefPubMed

Titel: Relapse of chronic myeloid leukemia-chronic phase 14 years after allogeneic hematopoietic stem cell transplantation
verfasst von: Daigo Akahane
Yoshikazu Ito
Masahiko Sumi
Tetsuzo Tauchi
Yukihiko Kimura
Kazuma Ohyashiki
Publikationsdatum: 01.07.2008
Verlag: Springer Japan
Erschienen in: International Journal of Hematology / Ausgabe 1/2008
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774
DOI: https://doi.org/10.1007/s12185-008-0092-5

Neu im Fachgebiet Onkologie

18.04.2024 | Wirbelsäulenmetastase | Nachrichten

Springer Medizin

Relapse of chronic myeloid leukemia-chronic phase 14 years after allogeneic hematopoietic stem cell transplantation

Excerpt

Neu im Fachgebiet Onkologie

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Manche Gestagene können das Risiko für Meningeome erhöhen

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Update Onkologie

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2008

Karyotypically independent clones with del(11q) and trisomy 10 in acute myeloid leukemia: trisomy 10 may appear as an additional change

A safety, pharmacokinetic and pharmacodynamic investigation of deferasirox (Exjade®, ICL670) in patients with transfusion-dependent anemias and iron-overload: a Phase I study in Japan

Periostin and bone marrow fibrosis

Epstein–Barr virus-associated T-cell lymphoma in an adult patient: prominent infiltrates within the liver portal area revealed by autopsy

Visual disturbance comorbid with hallucination caused by voriconazole in the Japanese population

Iron chelation therapy in the myelodysplastic syndromes and aplastic anemia: a review of experience in South Korea

Neu im Fachgebiet Onkologie

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Manche Gestagene können das Risiko für Meningeome erhöhen

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Update Onkologie